Medifron DBT Co. Ltd Net Assets
Medifron DBT Co. Ltd net assets. Based on the latest financial reports, Medifron DBT Co. Ltd (065650) has net assets worth ₩27.00 Billion KRW (≈ $18.30 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩113.62 Billion ≈ $77.00 Million USD) and total liabilities (₩86.61 Billion ≈ $58.70 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 065650 net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩27.00 Billion |
| % of Total Assets | 23.77% |
| Annual Growth Rate | -3.49% |
| 5-Year Change | -37.22% |
| 10-Year Change | -26.51% |
| Growth Volatility | 32.28 |
Net Assets of Medifron DBT Co. Ltd (2014–2024)
Net assets of Medifron DBT Co. Ltd from 2014 to 2024. This chart illustrates how Medifron DBT Co. Ltd's net assets have evolved over time, based on quarterly financial data. See 065650 net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Medifron DBT Co. Ltd (2014–2024)
The table below shows the annual net assets of Medifron DBT Co. Ltd from 2014 to 2024. For live market cap and overall valuation, see 065650 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩17.49 Billion ≈ $11.85 Million |
-52.60% |
| 2023-12-31 | ₩36.89 Billion ≈ $25.00 Million |
+18.66% |
| 2022-12-31 | ₩31.09 Billion ≈ $21.07 Million |
-26.48% |
| 2021-12-31 | ₩42.29 Billion ≈ $28.66 Million |
+51.82% |
| 2020-12-31 | ₩27.86 Billion ≈ $18.88 Million |
+57.47% |
| 2019-12-31 | ₩17.69 Billion ≈ $11.99 Million |
-7.85% |
| 2018-12-31 | ₩19.20 Billion ≈ $13.01 Million |
-22.44% |
| 2017-12-31 | ₩24.75 Billion ≈ $16.77 Million |
-3.22% |
| 2016-12-31 | ₩25.57 Billion ≈ $17.33 Million |
+7.46% |
| 2015-12-31 | ₩23.80 Billion ≈ $16.13 Million |
-4.58% |
| 2014-12-31 | ₩24.94 Billion ≈ $16.90 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Medifron DBT Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12944001090000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Medifron DBT Co. Ltd Net Assets Breakdown (December 2024)
Medifron DBT Co. Ltd net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩53.34 Billion | 305.00% |
| Other Components | ₩106.83 Billion | 610.85% |
| Total Equity | ₩17.49 Billion | 100.00% |
Medifron DBT Co. Ltd Competitors by Market Cap
The table below lists competitors of Medifron DBT Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nukkleus Inc
NASDAQ:NUKK
|
$12.65 Million |
|
Optimi Health Corp. Common Shares
NASDAQ:OPTH
|
$12.65 Million |
|
Scibase AB
ST:SCIB
|
$12.65 Million |
|
COINSILIUM GROUP LTD
F:5CT
|
$12.67 Million |
|
Turiya Bhd
KLSE:4359
|
$12.63 Million |
|
Intrasense
PA:ALINS
|
$12.62 Million |
|
Starr Peak Exploration Ltd
V:STE
|
$12.61 Million |
|
Keynote Financial Services Limited
NSE:KEYFINSERV
|
$12.59 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medifron DBT Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 36,892,838,020 to 17,489,044,000, a change of -19,403,794,020 (-52.6%).
- Net loss of 80,357,139,610 reduced equity.
- Share repurchases of 42,003,999,650 reduced equity.
- New share issuances of 42,003,999,650 increased equity.
- Other factors increased equity by 60,953,345,590.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-80.36 Billion | -459.47% |
| Share Repurchases | ₩42.00 Billion | -240.17% |
| Share Issuances | ₩42.00 Billion | +240.17% |
| Other Changes | ₩60.95 Billion | +348.52% |
| Total Change | ₩- | -52.60% |
Book Value vs Market Value Analysis
This analysis compares Medifron DBT Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.07x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.50x to 1.07x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩934.42 | ₩1401.00 | x |
| 2017-12-31 | ₩840.71 | ₩1401.00 | x |
| 2018-12-31 | ₩652.07 | ₩1401.00 | x |
| 2019-12-31 | ₩600.90 | ₩1401.00 | x |
| 2020-12-31 | ₩748.83 | ₩1401.00 | x |
| 2021-12-31 | ₩7756.87 | ₩1401.00 | x |
| 2022-12-31 | ₩660.90 | ₩1401.00 | x |
| 2023-12-31 | ₩5704.02 | ₩1401.00 | x |
| 2024-12-31 | ₩1313.59 | ₩1401.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medifron DBT Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -459.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -137.45%
- • Asset Turnover: 0.97x
- • Equity Multiplier: 3.45x
- Recent ROE (-459.47%) is below the historical average (-61.29%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -34.09% | -157.24% | 0.20x | 1.06x | ₩-11.00 Billion |
| 2015 | -7.18% | -20.79% | 0.27x | 1.30x | ₩-4.09 Billion |
| 2016 | -15.49% | -30.25% | 0.47x | 1.09x | ₩-6.52 Billion |
| 2017 | -46.27% | -54.77% | 0.80x | 1.06x | ₩-13.93 Billion |
| 2018 | -28.98% | -27.97% | 0.92x | 1.12x | ₩-7.48 Billion |
| 2019 | -10.06% | -10.22% | 0.89x | 1.10x | ₩-3.55 Billion |
| 2020 | -12.64% | -11.21% | 0.67x | 1.70x | ₩-6.31 Billion |
| 2021 | -15.98% | -13.72% | 1.00x | 1.16x | ₩-10.99 Billion |
| 2022 | -38.68% | -26.55% | 0.81x | 1.79x | ₩-15.13 Billion |
| 2023 | -5.31% | -4.57% | 0.77x | 1.51x | ₩-5.65 Billion |
| 2024 | -459.47% | -137.45% | 0.97x | 3.45x | ₩-82.11 Billion |
Industry Comparison
This section compares Medifron DBT Co. Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $417,529,273,243
- Average return on equity (ROE) among peers: -6.28%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medifron DBT Co. Ltd (065650) | ₩27.00 Billion | -34.09% | 3.21x | $12.64 Million |
| ORIENTBIO Inc. (002630) | $97.94 Billion | -19.53% | 0.76x | $96.19 Million |
| Green Cross (005250) | $1.97 Trillion | 1.67% | 0.83x | $290.81 Million |
| Green Cross Holdings Preference Shares (005257) | $1.67 Trillion | 10.22% | 0.94x | $2.85 Million |
| Pharmicell (005690) | $86.44 Billion | 7.32% | 0.15x | $367.60 Million |
| GeneOne Life Science Inc (011000) | $111.49 Billion | -69.75% | 0.35x | $32.81 Million |
| HLB Co. Ltd (028300) | $88.75 Billion | -14.89% | 1.10x | $3.02 Billion |
| Mgenplus Co. Ltd. (032790) | $18.79 Billion | 0.00% | 1.65x | $19.98 Million |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $13.93 Million |
| Seoulin Bioscience Co.Ltd (038070) | $45.30 Billion | 4.03% | 0.46x | $21.44 Million |
| Hyundai Bioscience Co. Ltd (048410) | $60.94 Billion | 0.00% | 2.69x | $356.42 Million |
About Medifron DBT Co. Ltd
Hyper Corporation Inc., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. Its products under development include TRPV1 Antagonist and TRPV1 Agonist for neuropathic pain; and anti-oligomerization of beta-amyloid, receptor for advanced glycation endproduct modulator, and early diagnosis kits for AD… Read more